At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 12, 2026 at 08:00 ET
Cogent Biosciences reported updated Phase 2 APEX trial results for bezuclastinib in advanced systemic mastocytosis (AdvSM) at EHA 2026, showing a 65% objective response rate per mIWG criteria and 81% per PPR criteria, with 91% of patients achieving ≥50% reduction in KIT D816V variant allele frequency. The company plans to submit an NDA in June 2026 and expects commercial launch later this year.
- Updated APEX trial data: 65% ORR per mIWG criteria (CR+CRh+PR+CI) and 81% ORR per PPR criteria in AdvSM patients.
- 91% of patients achieved ≥50% reduction in KIT D816V variant allele frequency; 89% had ≥50% reduction in bone marrow mast cells or clearance of aggregates.
- 12-month PFS rate of 79% and 12-month OS rate of 87%.
- NDA submission for bezuclastinib in AdvSM planned for June 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access